BioCentury
ARTICLE | Company News

Arch Biopartners deal

December 6, 2010 8:00 AM UTC

Arch received an option to purchase the remaining 33% stake in its Colorado Cancer Therapeutics Inc. subsidiary for a total of C$800,000 (US$785,520) from two minority shareholders. Upon exercise, ea...